Adial Pharmaceuticals (NASDAQ:ADIL) Trading Down 3.9% – Time to Sell?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) fell 3.9% on Tuesday . The stock traded as low as $0.2146 and last traded at $0.2163. 535,052 shares changed hands during mid-day trading, an increase of 76% from the average session volume of 303,396 shares. The stock had previously closed at $0.2250.

Analyst Ratings Changes

Several analysts have recently weighed in on ADIL shares. Maxim Group upgraded Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, September 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Adial Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $1.50.

Adial Pharmaceuticals Price Performance

The company has a market capitalization of $6.01 million, a price-to-earnings ratio of -0.29 and a beta of 1.19. The business has a fifty day moving average price of $0.27 and a 200 day moving average price of $0.34.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Research analysts anticipate that Adial Pharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 0.60% of Adial Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.